Author of

• 11481

  +

  P2.02 - Poster Session 2 - Novel Cancer Genes and Pathways (ID 148)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Biology
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/29/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11491

    +

    P2.02-010 - Frequency of ALK Gene Rearrangement in Saudi Lung Cancer (ID 1864)

    12:03 - 12:20  |  Author(s): P. Bavi
    • Abstract

    Background
    Lung carcinoma is the fifth common cancer affecting Saudi men. Recently, translocation of the anaplastic lymphoma kinase (ALK) gene is found to play a predictive role in adenocarcinoma tumor genesis. ALK gene rearrangement can identify patients with adenocarcinoma who are sensitive to ALK inhibitors. However, no data are available on the prevalence of ALK rearrangements changes in Middle Eastern population. Therefore, we carried out this study to evaluate the prevalence of ALK rearrangements in lung adenocarcinoma of Saudi patients.

    Methods
    ALK gene rearrangements were studied using fluorescence in situ hybridization (FISH) on 97 adenocarcinoma samples utilizing tissue microarray format. ALK gene translocations identified by BAC clone RP11-328L16 were studied by the break part probe from Vysis (Abott Molecular, Il, USA).

    Results
    Ninety seven (97) lung adenocarcinoma cases were evaluated. There were 3 cases exhibited ALK gene rearrangement (3%). All of these 3 cases was moderately differentiated adenocarcinoma. None of our cases showed signet cells or abundant intracellular mucin.

    Conclusion
    This is the first study that reveals frequency of ALK translocation in a ethically unique cohort of Saudi lung cancer patients. The findings of this study show that incidence of ALK adenocarcinoma is similar to the published western data and these patients can benefit from targeted therapy like Crizotinib- a dual ALK and MET inhibitor that has shown promising results in clinical trials.